Effect of Macitentan on Hospitalizations: Results From the SERAPH IN Trial

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10314131" target="_blank" >RIV/00216208:11110/15:10314131 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/15:10314131
Result on the web
<a href="http://dx.doi.org/10.1016/j.jchf.2014.07.013" target="_blank" >http://dx.doi.org/10.1016/j.jchf.2014.07.013</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jchf.2014.07.013" target="_blank" >10.1016/j.jchf.2014.07.013</a>

Result language
angličtina
Original language name
Effect of Macitentan on Hospitalizations: Results From the SERAPH IN Trial
Original language description
OBJECTIVES: This study sought to evaluate the effect of macitentan on hospitalization of patients with symptomatic pulmonary arterial hypertension (PAH). BACKGROUND: PAH is a progressive, life-threatening disease often requiring hospitalization. METHODS:In the multicenter, double-blind, randomized, event-driven, phase III SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) trial, patients with symptomatic PAH were randomized (1:1:1) toreceive placebo or 3 mg or 10 mg of macitentan. Effects of macitentan on the risk, rate, and number of hospital days for all-cause and PAH-related hospitalizations were compared with those for placebo. Risk and causes of hospitalizations unrelated to PAHwere investigated.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)